ZP10068
Complement C3 inhibitor for targeting chronic inflammation
ZP10068 is an investigational selective and long-acting inhibitor of Complement C3, which has the potential to treat a number of complement mediated diseases.
The complement system is a part of the innate immune system, and a central component of the complement cascade is the C3 protein. Altered activation of the complement cascade is implicated in many immune-mediated diseases and in particular rare diseases such as paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, myasthenia gravis and C3 glomerulopathy.
- PROGRAM ZP10068
- Preclinical
Development status
We have completed the pre-clinical activities with ZP10068 and the next step in development is to initiate a first-in-human clinical trial.
ZP10068 is an investigational compound whose safety and efficacy have not been evaluated or approved for marketing by any regulatory authority.
Chronic Inflammation
More about the disease area
Inflammation is a part of the body's natural defense system. However, when it lasts too long and becomes chronic, inflammation can damage the body's tissue that inflammation normally works to heal.
